AI Drug Discovery Pioneer Predictive Oncology to Be Acquired by Renovaro, Inc.
A leader in AI-driven drug discovery, Predictive Oncology Inc. (NASDAQ: POAI), has announced its entry into a binding letter of intent to be acquired by Renovaro, Inc. (NASDAQ: RENB) in exchange for preferred stock of Renovaro.
Both companies share a strong commitment to advancing cancer care through early diagnosis, biomarker discovery, and targeted therapies. By merging their proprietary AI/ML platforms, which offer complementary technical advantages, they aim to accelerate drug discovery while reducing the risks associated with drug development. The merger also promises significant operational cost savings, estimated to reduce combined expenses by over 30% in the near term.
Raymond Vennare, Chairman and CEO of Predictive Oncology, emphasized the strategic alignment, stating, “Our AI-driven drug discovery platform, combined with our extensive biobank of over 150,000 tumor samples, 200,000 pathology slides, and decades of drug response data, complements Renovaro’s expertise in multi-disciplinary AI, multi-omics, and multi-modal data. Together, we can drive transformative advancements in oncology.”
Merger Terms:
Transaction Structure: Predictive Oncology will merge into Renovaro, with shareholders receiving newly created preferred stock on a 1:1 exchange for their common shares.
Preferred Stock Features: Automatically redeemable for $3.00 per share after 18 months, with optional conversion to freely tradable Renovaro common stock once its share price sustains $4.50 for 30 consecutive trading days. Renovaro retains rights to redeem the preferred stock under specified conditions.
Warrant Clause: If Series A and Series B warrant holders of Predictive Oncology do not exercise their warrants by January 15, 2025, Renovaro will purchase up to 2.33M Predictive Oncology shares at $1.07 each.
Conditions: The merger requires definitive documentation by February 28, 2025, a minimum $15M fundraising by Renovaro, and Predictive Oncology shareholder approval. If shareholder approval fails after funding, Renovaro will receive a two-year exclusive royalty-free license to Predictive Oncology’s biobank and tumor-specific 3D cell culture models.
Next Steps:
The companies are working to finalize leadership team and board compositions, along with R&D priorities and operational details for the combined entity. Both parties are committed to expediting the transaction to deliver innovative oncology-focused technology for improved patient outcomes.
It remains uncertain whether the transaction will proceed, and Predictive Oncology does not plan to disclose further updates unless required by its Board or legal obligations.
